Citations (17)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (2)
Jingyang Su, Menglei Wang, Yue Fu, Jiang Yan, Yuezhong Shen, Jing Jiang, Jue Wang, Jinhua Lu, Yazhen Zhong, Xianlei Lin, Zechen Lin & Shengyou Lin. (2022) Efficacy and safety of multi-kinase inhibitors in patients with radioiodine-refractory differentiated thyroid cancer: a systematic review and meta-analysis of clinical trials. Expert Review of Anticancer Therapy 22:9, pages 999-1008.
Read now
Read now
He-Jiun Jiang, Yen-Hsiang Chang, Yen-Hao Chen, Che-Wei Wu, Pei-Wen Wang & Pi-Jung Hsiao. (2021) Low Dose of Lenvatinib Treatment for Patients of Radioiodine-Refractory Differentiated Thyroid Carcinoma – A Real-World Experience. Cancer Management and Research 13, pages 7139-7148.
Read now
Read now
Articles from other publishers (15)
Domenica Lorusso, Nicoletta Colombo, Antonio Casado Herraez, Alessandro D. Santin, Emeline Colomba, David Scott Miller, Keiichi Fujiwara, Sandro Pignata, Sally E. Baron-Hay, Isabelle Laure Ray-Coquard, Ronnie Shapira-Frommer, Yong Man Kim, Mary McCormack, Rachid Massaad, Allison Martin Nguyen, Qi Zhao, Jodi McKenzie, Vimalanand S. Prabhu & Vicky Makker. (2023) Health-Related Quality of Life in Patients With Advanced Endometrial Cancer Treated With Lenvatinib Plus Pembrolizumab or Treatment of Physician’s Choice. European Journal of Cancer 186, pages 172-184.
Crossref
Crossref
Matthew H. Taylor, Sophie Leboulleux, Yury Panaseykin, Bhavana Konda, Christelle de La Fouchardiere, Brett G. M. Hughes, Andrew G. Gianoukakis, Young Joo Park, Ilia Romanov, Monika K. Krzyzanowska, Diana Garbinsky, Bintu Sherif, Jie Janice Pan, Terri A. Binder, Nicholas Sauter, Ran Xie & Marcia S. Brose. (2022) Health‐related quality‐of‐life analyses from a multicenter, randomized, double‐blind phase 2 study of patients with differentiated thyroid cancer treated with lenvatinib 18 or 24 mg/day. Cancer Medicine 12:4, pages 4332-4342.
Crossref
Crossref
R. Motzer, C. Porta, B. Alekseev, S. Y. Rha, T. K. Choueiri, M. J. Mendez-Vidal, S. H. Hong, A. Kapoor, J. C. Goh, M. Eto, L. Bennett, J. Wang, J. J. Pan, T. L. Saretsky, R. F. Perini, C. S. He, K. Mody & D. Cella. (2022) Health-related quality-of-life outcomes in patients with advanced renal cell carcinoma treated with lenvatinib plus pembrolizumab or everolimus versus sunitinib (CLEAR): a randomised, phase 3 study. Cancer Urology 18:2, pages 39-57.
Crossref
Crossref
Matteo Trevisan, Carla Colombo, Noemi Giancola, Claudia Moneta, Gianlorenzo Dionigi, Laura Fugazzola & Simone De Leo. (2022) Lenvatinib-induced hypocalcaemia due to transient primary hypoparathyroidism. Endocrine 78:1, pages 197-200.
Crossref
Crossref
Robert Motzer, Camillo Porta, Boris Alekseev, Sun Young Rha, Toni K Choueiri, Maria Jose Mendez-Vidal, Sung-Hoo Hong, Anil Kapoor, Jeffrey C Goh, Masatoshi Eto, Lee Bennett, Jinyi Wang, Jie Janice Pan, Todd L Saretsky, Rodolfo F Perini, Cixin Steven He, Kalgi Mody & David Cella. (2022) Health-related quality-of-life outcomes in patients with advanced renal cell carcinoma treated with lenvatinib plus pembrolizumab or everolimus versus sunitinib (CLEAR): a randomised, phase 3 study. The Lancet Oncology 23:6, pages 768-780.
Crossref
Crossref
Zhongqin Gong, Hao Jia, Lingbin Xue, Dongcai LI, Xianhai Zeng, Minghui Wei, Zhimin Liu, Michael C. F. Tong & George G. Chen. (2021) The emerging role of transcription factor FOXP3 in thyroid cancer. Reviews in Endocrine and Metabolic Disorders 23:3, pages 421-429.
Crossref
Crossref
Tomohiro Enokida & Makoto Tahara. (2021) Management of VEGFR-Targeted TKI for Thyroid Cancer. Cancers 13:21, pages 5536.
Crossref
Crossref
Vicky Makker, Matthew H. Taylor, Ana Oaknin, Antonio Casado Herraez, Robert Orlowski, Lea Dutta, Min Ren, Melissa Zale & David M. O'Malley. (2021) Characterization and Management of Adverse Reactions in Patients with Advanced Endometrial Carcinoma Treated with Lenvatinib Plus Pembrolizumab. The Oncologist 26:9, pages e1599-e1608.
Crossref
Crossref
Jiapeng Huang, Wei Sun, Qingfu Zhang, Zhihong Wang, Wenwu Dong, Dalin Zhang, Chengzhou Lv, Liang Shao, Ping Zhang & Hao Zhang. (2021) Clinicopathological Characteristics and Prognosis of Poorly Differentiated Thyroid Carcinoma Diagnosed According to the Turin Criteria. Endocrine Practice 27:5, pages 401-407.
Crossref
Crossref
Frederik A. Verburg, Holger Amthauer, Ina Binse, Ingo Brink, Andreas Buck, Andreas Darr, Christine Dierks, Christine Koch, Ute König, Michael C. Kreissl, Markus Luster, Christoph Reuter, Klemens Scheidhauer, Holger Sven Willenberg, Andreas Zielke & Matthias Schott. (2021) Questions and Controversies in the Clinical Application of Tyrosine Kinase Inhibitors to Treat Patients with Radioiodine-Refractory Differentiated Thyroid Carcinoma: Expert Perspectives. Hormone and Metabolic Research 53:03, pages 149-160.
Crossref
Crossref
Kei Saito, Hideki Fujii, Keiji Kono, Ken Hirabayashi, Satoshi Yamatani, Kentaro Watanabe, Shunsuke Goto, Shohei Komatsu, Takumi Fukumoto & Shinichi Nishi. (2021) Changes in blood pressure during treatment with the tyrosine kinase inhibitor lenvatinib. Clinical Kidney Journal 14:1, pages 325-331.
Crossref
Crossref
Jie Li, Bo Zhang, Yang Bai, Yonghong Liu, Buyong Zhang & Jian Jin. (2020) Health-related quality of life analysis in differentiated thyroid carcinoma patients after thyroidectomy. Scientific Reports 10:1.
Crossref
Crossref
Alice NervoAlberto RagniMarco GalloAndrea FerrarisPaolo FonioAlessandro PiovesanEmanuela Arvat. (2020) Symptomatic Biliary Disorders During Lenvatinib Treatment for Thyroid Cancer: An Underestimated Problem. Thyroid 30:2, pages 229-236.
Crossref
Crossref
Antonio Matrone, Maria Cristina Campopiano, Alice Nervo, Giulia Sapuppo, Martina Tavarelli & Simone De Leo. (2020) Differentiated Thyroid Cancer, From Active Surveillance to Advanced Therapy: Toward a Personalized Medicine. Frontiers in Endocrinology 10.
Crossref
Crossref
Benedetta Donati & Alessia Ciarrocchi. (2019) Telomerase and Telomeres Biology in Thyroid Cancer. International Journal of Molecular Sciences 20:12, pages 2887.
Crossref
Crossref